Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer.
Cisplatin
DNA damage
HRD
Synthetic lethal
TNBC
miR-26a-5p
Journal
Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353
Informations de publication
Date de publication:
26 06 2023
26 06 2023
Historique:
received:
18
05
2022
accepted:
24
05
2023
medline:
28
6
2023
pubmed:
27
6
2023
entrez:
26
6
2023
Statut:
epublish
Résumé
DNA damage and DNA damage repair (DDR) are important therapeutic targets for triple-negative breast cancer (TNBC), a subtype with limited chemotherapy efficiency and poor outcome. However, the role of microRNAs in the therapy is emerging. In this study, we explored whether miR-26a-5p could act as BRCAness and enhance chemotherapy sensitivity in TNBC. Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to detect the expression of miR-26a-5p in breast cancer tissues and cell lines. CCK-8 was used to measure drug sensitivity in concentration gradient and time gradient. Comet assay was used to detect DNA damage. Flow cytometry was performed to examine apoptosis. Moreover, we used western blot and immunofluorescence to detect biomarkers. Luciferase reporter assay was performed to verify the combination of miR-26a-5p and 3'UTR of target gene. Hormone deprivation and stimulation assay were used to validate the effect of hormone receptors on the expression of miR-26a-5p. Chromatin immunoprecipitation (ChIP) assays were used to verify the binding sites of ER-a or PR with the promoter of miR-26a-5p. Animal experiments were performed to the effect of miR-26a-5p on Cisplatin treatment. The expression of miR-26a-5p was significantly downregulated in TNBC. Overexpressing miR-26a-5p enhanced the Cisplatin-induced DNA damage and following apoptosis. Interestingly, miR-26a-5p promoted the expression of Fas without Cisplatin stimulating. It suggested that miR-26a-5p provided a hypersensitivity state of death receptor apoptosis and promoted the Cisplatin sensitivity of TNBC cells in vitro and in vivo. Besides, miR-26a-5p negatively regulated the expression of BARD1 and NABP1 and resulted in homologous recombination repair defect (HRD). Notably, overexpressing miR-26a-5p not only facilitated the Olaparib sensitivity of TNBC cells but also the combination of Cisplatin and Olaparib. Furthermore, hormone receptors functioned as transcription factors in the expression of miR-26a-5p, which explained the reasons that miR-26a-5p expressed lowest in TNBC. Taken together, we reveal the important role of miR-26a-5p in Cisplatin sensitivity and highlight its new mechanism in DNA damage and synthetic lethal.
Sections du résumé
BACKGROUND
DNA damage and DNA damage repair (DDR) are important therapeutic targets for triple-negative breast cancer (TNBC), a subtype with limited chemotherapy efficiency and poor outcome. However, the role of microRNAs in the therapy is emerging. In this study, we explored whether miR-26a-5p could act as BRCAness and enhance chemotherapy sensitivity in TNBC.
METHODS
Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to detect the expression of miR-26a-5p in breast cancer tissues and cell lines. CCK-8 was used to measure drug sensitivity in concentration gradient and time gradient. Comet assay was used to detect DNA damage. Flow cytometry was performed to examine apoptosis. Moreover, we used western blot and immunofluorescence to detect biomarkers. Luciferase reporter assay was performed to verify the combination of miR-26a-5p and 3'UTR of target gene. Hormone deprivation and stimulation assay were used to validate the effect of hormone receptors on the expression of miR-26a-5p. Chromatin immunoprecipitation (ChIP) assays were used to verify the binding sites of ER-a or PR with the promoter of miR-26a-5p. Animal experiments were performed to the effect of miR-26a-5p on Cisplatin treatment.
RESULTS
The expression of miR-26a-5p was significantly downregulated in TNBC. Overexpressing miR-26a-5p enhanced the Cisplatin-induced DNA damage and following apoptosis. Interestingly, miR-26a-5p promoted the expression of Fas without Cisplatin stimulating. It suggested that miR-26a-5p provided a hypersensitivity state of death receptor apoptosis and promoted the Cisplatin sensitivity of TNBC cells in vitro and in vivo. Besides, miR-26a-5p negatively regulated the expression of BARD1 and NABP1 and resulted in homologous recombination repair defect (HRD). Notably, overexpressing miR-26a-5p not only facilitated the Olaparib sensitivity of TNBC cells but also the combination of Cisplatin and Olaparib. Furthermore, hormone receptors functioned as transcription factors in the expression of miR-26a-5p, which explained the reasons that miR-26a-5p expressed lowest in TNBC.
CONCLUSIONS
Taken together, we reveal the important role of miR-26a-5p in Cisplatin sensitivity and highlight its new mechanism in DNA damage and synthetic lethal.
Identifiants
pubmed: 37365643
doi: 10.1186/s13058-023-01663-y
pii: 10.1186/s13058-023-01663-y
pmc: PMC10294332
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
MicroRNAs
0
Carrier Proteins
0
Hormones
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
75Informations de copyright
© 2023. The Author(s).
Références
Oncogene. 2003 Oct 20;22(47):7265-79
pubmed: 14576837
Breast Cancer Res Treat. 2012 Feb;131(3):765-75
pubmed: 21452023
Proteins. 2020 Feb;88(2):319-326
pubmed: 31443132
Trends Mol Med. 2006 Sep;12(9):440-50
pubmed: 16899408
Semin Cell Dev Biol. 2019 Feb;86:121-128
pubmed: 29577982
Nucleic Acids Res. 2021 Sep 7;49(15):8556-8572
pubmed: 34329471
J Biol Chem. 2009 Aug 28;284(35):23525-31
pubmed: 19605351
Genomics Proteomics Bioinformatics. 2020 Apr;18(2):120-128
pubmed: 32858223
Gastroenterology. 2009 Jan;136(1):17-25
pubmed: 19049808
Onco Targets Ther. 2020 Mar 27;13:2537-2550
pubmed: 32273724
Pharm Res. 2013 Apr;30(4):1008-16
pubmed: 23184229
Photochem Photobiol. 2011 Nov-Dec;87(6):1230-9
pubmed: 21883247
Nat Rev Mol Cell Biol. 2020 May;21(5):284-299
pubmed: 32094664
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W169-73
pubmed: 23680784
Nucleic Acids Res. 2015 Jul 1;43(W1):W460-6
pubmed: 25977294
Br J Cancer. 2014 Oct 14;111(8):1532-41
pubmed: 25101563
J Biopharm Stat. 2010 Sep;20(5):954-64
pubmed: 20721784
Kaohsiung J Med Sci. 2019 Aug;35(8):467-473
pubmed: 31063232
J Biol Chem. 2002 Jun 14;277(24):21315-24
pubmed: 11925436
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Database (Oxford). 2021 Feb 18;2021:
pubmed: 33599248
Nat Rev Clin Oncol. 2022 Feb;19(2):91-113
pubmed: 34754128
Clinics (Sao Paulo). 2018 Sep 06;73(suppl 1):e478s
pubmed: 30208165
Cancer Manag Res. 2020 Apr 30;12:3013-3022
pubmed: 32431544
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
J Cell Biochem. 2019 Jun;120(6):10756-10766
pubmed: 30652345
Database (Oxford). 2013 Jan 15;2013:bas060
pubmed: 23325629
Trends Cell Biol. 2019 Sep;29(9):740-751
pubmed: 31362850
Cancer Manag Res. 2020 Nov 17;12:11723-11733
pubmed: 33235501
Semin Cell Dev Biol. 2022 Apr;124:99-113
pubmed: 33865701
Kidney Int. 2008 May;73(9):994-1007
pubmed: 18272962
J Nucl Med. 2016 Feb;57 Suppl 1:9S-16S
pubmed: 26834110
FEBS Lett. 2015 Jul 8;589(15):1958-65
pubmed: 26028311
J Cell Sci. 2003 Feb 15;116(Pt 4):585-6
pubmed: 12538758
Nat Rev Cancer. 2016 Feb;16(2):110-20
pubmed: 26775620
Clin Cancer Res. 2008 Mar 1;14(5):1291-5
pubmed: 18316546
Eur J Cancer. 2010 May;46(8):1445-55
pubmed: 20202822
Oncogene. 2012 Apr 12;31(15):1869-83
pubmed: 21892204
Nat Rev Cancer. 2021 Nov;21(11):701-717
pubmed: 34376827
Nucleic Acids Res. 2021 May 7;49(8):4239-4257
pubmed: 33744950
N Engl J Med. 2021 Jun 24;384(25):2394-2405
pubmed: 34081848
Nucleic Acids Res. 2022 Jan 7;50(D1):D165-D173
pubmed: 34850907
Cancer Res. 2015 Apr 1;75(7):1298-310
pubmed: 25627978
Int J Mol Sci. 2020 May 28;21(11):
pubmed: 32481735
Int J Biochem Cell Biol. 2016 Mar;72:1-17
pubmed: 26738429
Lancet Oncol. 2017 Oct;18(10):1386-1396
pubmed: 28870611
Cell Rep. 2019 Aug 27;28(9):2345-2357.e5
pubmed: 31461651